Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Authors :: Colm Power
Sinead Toomey
John Crown
Norma O'Donovan
Leonie S. Young
Ausra Teiserkiene
Malgorzata Milewska
Oscar S. Breathnach
M. John Kennedy
Deirdre Duke
Alex J Eustace
William Grogan
Darran P. O'Connor
Niamh Hambly
Bryan T. Hennessy
William M. Gallagher
Janice M. Walshe
Joanna Fay
Elaine W. Kay
Arnold D.K. Hill
Source :: Journal of Clinical Oncology. 34:591-591
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 591Background: TCGA analysis revealed that somatic EGFR, ERBB2, ERBB3 and ERBB4 mutations (ERBB family mutations) occur alone or co-occur with somatic PIK3CA mutations in 19% of HER2-positive breas...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
ERBB Family
business.industry
Somatic cell
Internal medicine
HER2 Positive Breast Cancer
Medicine
ERBB3
skin and connective tissue diseases
business
neoplasms
Pathological
ERBB4

Full Text Access

Tools